跳至主要内容
临床试验/EUCTR2021-006550-31-ES
EUCTR2021-006550-31-ES进行中(未招募)1 期

Efficacy and Security of BempeDoic acid in Acute Coronary Syndrome - ES-BempeDACS

SPANISH SOCIETY OF CARDIOLOGY0 个研究点目标入组 206 人开始时间: 2022年1月10日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
206

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Persistent LDL-C =70 mg/dl despite stable baseline regimen (=4 weeks) of high-potency statins, OR
  • 2. LDL-C =100 mg/dl in patients who do not tolerate high-potency statins or who are not treated with high-potency statins, including statin-naïve patients.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 103
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 103

排除标准

  • 1) Patients under 18 years of age, pregnant or breastfeeding.
  • 2) Patients with absolute or relative contraindication to bempedoic acid or ezetimibe.
  • 3) Patients with Triglycerides =400 mg / dL.
  • 4) Patients treated with fibrates and/or PCSK9 inhibitor.
  • 5) Patients with limited life expectancy (<1 year) at the judgment of the responsible physician.
  • 6) Patients in another clinical trial.

研究者

发起方
SPANISH SOCIETY OF CARDIOLOGY

相似试验